Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO NASDAQ:CDMO NASDAQ:MRUS NYSE:OGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$52.08-4.1%$50.63$21.34▼$58.40$4.15B-0.151.06 million shs881,281 shsCDMOAvid Bioservices$12.50+0.1%$12.50$8.74▼$12.51$799.18M1.391.45 million shs3.07 million shsMRUSMerus$63.26+3.0%$52.47$33.19▼$63.43$4.38B1733,967 shs1.06 million shsOGNOrganon & Co.$9.46-1.9%$9.52$8.01▼$23.10$2.46B0.63.63 million shs3.13 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics0.00%+0.99%-5.14%+38.40%+92.32%CDMOAvid Bioservices0.00%0.00%0.00%0.00%+27.89%MRUSMerus0.00%+16.07%+20.29%+46.91%+11.87%OGNOrganon & Co.0.00%-4.83%-4.31%-14.84%-55.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics3.7714 of 5 stars3.51.00.04.73.30.80.0CDMOAvid Bioservices0.8984 of 5 stars1.00.00.04.50.01.70.6MRUSMerus2.1665 of 5 stars3.61.00.00.02.62.50.0OGNOrganon & Co.4.8103 of 5 stars3.33.01.73.71.83.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$82.5058.41% UpsideCDMOAvid Bioservices 2.00Hold$12.25-1.96% DownsideMRUSMerus 3.14Buy$84.6433.79% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0090.27% UpsideCurrent Analyst Ratings BreakdownLatest CDMO, AKRO, MRUS, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.005/15/2025OGNOrganon & Co.Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.005/13/2025AKROAkero TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.005/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.005/5/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.005/2/2025OGNOrganon & Co.Evercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline4/28/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/ACDMOAvid Bioservices$139.91M5.71$0.15 per share80.92$3.02 per share4.14MRUSMerus$36.13M121.18N/AN/A$9.46 per share6.69OGNOrganon & Co.$6.29B0.39$4.93 per share1.92$1.83 per share5.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)CDMOAvid Bioservices-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%9/8/2025 (Estimated)MRUSMerus-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)OGNOrganon & Co.$864M$2.883.282.530.9811.92%227.43%7.34%8/5/2025 (Estimated)Latest CDMO, AKRO, MRUS, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025AKROAkero Therapeutics-$0.95N/AN/AN/AN/AN/A8/7/2025Q1 2025MRUSMerus-$1.17N/AN/AN/AN/AN/A8/5/2025Q2 2025OGNOrganon & Co.$0.93N/AN/AN/A$1.55 billionN/A5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/ACDMOAvid BioservicesN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.85%N/A2.78%N/ALatest CDMO, AKRO, MRUS, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0316.8016.80CDMOAvid Bioservices3.581.300.92MRUSMerusN/A5.865.86OGNOrganon & Co.16.491.671.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/ACDMOAvid Bioservices97.16%MRUSMerus96.14%OGNOrganon & Co.77.43%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%CDMOAvid Bioservices3.05%MRUSMerus4.57%OGNOrganon & Co.1.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.72 million74.08 millionOptionableCDMOAvid Bioservices32063.96 million62.01 millionOptionableMRUSMerus3769.21 million66.05 millionOptionableOGNOrganon & Co.4,000259.96 million254.86 millionNot OptionableCDMO, AKRO, MRUS, and OGN HeadlinesRecent News About These CompaniesOptimist Retirement Group LLC Raises Stock Holdings in Organon & Co. (NYSE:OGN)1 hour ago | marketbeat.comOGN SECURITIES NEWS: Did Organon & Co. ...1 hour ago | gurufocus.comOGN SECURITIES NEWS: Did Organon & Co. (NYSE:OGN) Commit Securities Fraud? Contact BFA Law by July 22 Class Action Deadline3 hours ago | globenewswire.comFoundry Partners LLC Lowers Holdings in Organon & Co. (NYSE:OGN)3 hours ago | marketbeat.comOGN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Organon & Co. ...July 19 at 5:22 PM | gurufocus.comOGN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important July 22 Deadline in Securities Class Action – OGNJuly 19 at 4:45 PM | globenewswire.comORGANON DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. ...July 19 at 11:31 AM | gurufocus.comORGANON DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. (OGN) Investors of the July 22nd Deadline and Urges Them to Inquire About Their Rights in Class Action LawsuitJuly 19 at 10:50 AM | globenewswire.comTUESDAY INVESTOR DEADLINE: Organon & Co. ...July 18 at 11:32 PM | gurufocus.comTUESDAY INVESTOR DEADLINE: Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 18 at 10:00 PM | prnewswire.comOrganon (OGN) Registers a Bigger Fall Than the Market: Important Facts to NoteJuly 18 at 6:51 PM | zacks.comORGANON 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Organon & Co. - OGNJuly 18 at 6:00 PM | businesswire.comOrganon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses; July ...July 18 at 5:01 PM | gurufocus.comOrganon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses; July 22, 2025 Deadline to file Lead Plaintiff MotionJuly 18 at 4:46 PM | globenewswire.comDeadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy ...July 18 at 12:08 PM | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co.of Class Action Lawsuit and Upcoming Deadlines - OGNJuly 18 at 12:00 PM | globenewswire.comDeadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitJuly 18 at 12:00 PM | globenewswire.comHussman Strategic Advisors Inc. Sells 84,000 Shares of Organon & Co. (NYSE:OGN)July 18 at 10:39 AM | marketbeat.comOGN SECURITIES FRAUD: Organon & Co. (NYSE:OGN) 27% Stock Drop Triggers Class Action Lawsuit ...July 18 at 10:31 AM | gurufocus.comLevi & Korsinsky Notifies Shareholders of Organon & Co. ...July 18 at 9:31 AM | gurufocus.comOGN SECURITIES FRAUD: Organon & Co. (NYSE:OGN) 27% Stock Drop Triggers Class Action Lawsuit – Contact BFA Law by July 22 Legal DeadlineJuly 18 at 9:07 AM | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDMO, AKRO, MRUS, and OGN Company DescriptionsAkero Therapeutics NASDAQ:AKRO$52.08 -2.25 (-4.14%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$52.74 +0.66 (+1.27%) As of 07/18/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Avid Bioservices NASDAQ:CDMOAvid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.Merus NASDAQ:MRUS$63.26 +1.82 (+2.96%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$63.24 -0.02 (-0.04%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Organon & Co. NYSE:OGN$9.46 -0.18 (-1.87%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$9.47 +0.01 (+0.10%) As of 07/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.